Lee Chung-Un, Song Wan, Koo Michael Jakun, Boo Youngjun, Chung Jae-Hoon, Kang Minyong, Sung Hyun-Hwan, Jeon Hwang-Gyun, Jeong Byong-Chang, Seo Seong-Il, Lee Hyun-Moo, Jeong Jeongyun, Jeon SeongSoo
Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Center for Health Promotion, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Diagnostics (Basel). 2022 Apr 21;12(5):1040. doi: 10.3390/diagnostics12051040.
To evaluate the utility of contemporary health screening (HS) in the diagnosis of bladder cancer (BCa).
We retrospectively reviewed 279,683 individuals who underwent HS between February 1995 and April 2015. Among these individuals, 74 were diagnosed with BCa within a year after the HS and were included in the analysis. Screen-detected BCa was defined as when a referral was made to a urologist due to microscopic hematuria (MH) on urinalysis, abnormal imaging, or any urological symptoms observed at the HS. Screen-undetected BCa was defined as when no referral was made to a urologist because of no abnormality observed at the HS, but a visit to a urological outpatient clinic later was followed by a BCa diagnosis. The incidences of screen-detected BCa and BCa in the Korean population were compared. Clinicopathological characteristics were compared between the screen-detected BCa and screen-undetected BCa groups.
The detection rate of BCa was 17.2 per 100,000, which exceeded the 2020 estimated national crude incidence rate of 9.3 per 100,000 by approximately 1.7 times. Among the 74 patients diagnosed with BCa within a year after HS, 48 (64.9%) had screen-detected BCa. The screen-detected BCa group had a higher T stage ( = 0.009) and grade ( = 0.019) than the screen-undetected BCa group. However, the overall survival was not significantly different between the two groups ( = 0.677). A positive correlation between the MH grade and the T stage was identified ( = 0.001).
Although HS is not focused on BCa screening, contemporary HS can contribute to the detection of BCa.
评估当代健康筛查（HS）在膀胱癌（BCa）诊断中的效用。
我们回顾性分析了1995年2月至2015年4月期间接受HS的279,683例个体。在这些个体中，74例在HS后一年内被诊断为BCa并纳入分析。筛查发现的BCa定义为因尿液分析中显微镜下血尿（MH）、影像学异常或HS时观察到的任何泌尿系统症状而转诊至泌尿科医生处。未筛查出的BCa定义为HS时未发现异常而未转诊至泌尿科医生处，但后来到泌尿外科门诊就诊后被诊断为BCa。比较韩国人群中筛查发现的BCa和BCa的发病率。比较筛查发现的BCa组和未筛查出的BCa组的临床病理特征。
BCa的检出率为每10万人17.2例，比2020年估计的全国粗发病率每10万人9.3例高出约1.7倍。在HS后一年内被诊断为BCa的74例患者中，48例（64.9%）为筛查发现的BCa。筛查发现的BCa组的T分期（P = 0.009）和分级（P = 0.019）高于未筛查出的BCa组。然而，两组的总生存率无显著差异（P = 0.677）。MH分级与T分期之间存在正相关（P = 0.001）。
尽管HS并非专注于BCa筛查，但当代HS有助于BCa的检测。
